Morgan Stanley
DRUG

Morgan Stanley’s Bright Minds Biosciences DRUG Stock Holding History

Morgan Stanley’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
18,599
-114,165
-86% -$8.96M ﹤0.01% 5084
2026
Q1 		$9.69M Buy
132,764
+642
+0.5% +$51.7K ﹤0.01% 3591
2025
Q4 		$10.3M Sell
132,122
-60,744
-31% -$4.06M ﹤0.01% 3584
2025
Q3 		$11.7M Buy
192,866
+30,797
+19% +$1.2M ﹤0.01% 3406
2025
Q2 		$4.23M Buy
162,069
+5,519
+4% +$165K ﹤0.01% 4191
2025
Q1 		$5.65M Sell
156,550
-11,090
-7% -$406K ﹤0.01% 3824
2024
Q4 		$6.04M Buy
+167,640
New +$5.9M ﹤0.01% 3844

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley's DRUG Position: Q2 2026 in Review

Morgan Stanley reduced its Bright Minds Biosciences (DRUG) stake by 86% in Q2 2026, selling an estimated $8.96M and leaving 18,599 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5084.

Morgan Stanley first reported a position in DRUG in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.7M in Q3 2025. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Morgan Stanley held 18,599 shares of Bright Minds Biosciences worth $1.31M as of Q2 2026.
  • Morgan Stanley sold 114,165 Bright Minds Biosciences shares in Q2 2026, an estimated $8.96M.
  • Bright Minds Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5084 holding.
  • Morgan Stanley first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Bright Minds Biosciences position peaked at $11.7M in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.